News

Company launches automated hematology analyzers in US


 

Hematology Analyzers

Sysmex XN-L Automated

Sysmex America, Inc. has launched its XN-L™ automated hematology analyzers in the US.

The company says this new, smaller XN-L line delivers the same clinical and operational value as its XN-Series™ to lower-volume hematology laboratories.

“The XN-Series has been our flagship hematology analyzer line, and, today, we expand our offering by introducing the XN-L Series to meet the demands of lower-volume facilities,” said Andy Hay, chief operating officer of Sysmex America.

“With an XN-L analyzer, clinicians can rely upon the same expanded complete blood count (CBC) featured in our XN-Series analyzers to assess and monitor patients. This expanded CBC goes well beyond the 3-part differential that is currently available to most of the low-volume segment today and can aid in the assessment of sepsis and other hematological disorders.”

The XN-L automated hematology analyzers offer a 6-part differential, including immature granulocyte analysis on each sample.

In addition, the XN-L Series offers optional software licenses for (1) a reticulocyte channel to aid in anemia management and (2) body fluid cell counts.

The XN-L analyzers will also be the first to feature BeyondCare Quality Monitor, a new approach to quality assurance.

“BeyondCare Quality Monitor, a Sysmex proprietary innovation, is a leading-edge, evidence-based QC and calibration verification management program that partners Sysmex with the laboratory to proactively monitor quality assurance metrics,” Hay said. “It will be standard on all XN-L hematology analyzers.

Additional information on XN-L analyzers is available on the Sysmex website at www.sysmex.com/XNL.

The XN-L analyzers will be available both directly through the company and through its distribution partners. Interested parties should contact their Sysmex representative or Sysmex distributor for complete details.

Recommended Reading

Countries with high malaria burden don’t receive research funding
MDedge Hematology and Oncology
FDA unveils plan to eliminate orphan designation backlog
MDedge Hematology and Oncology
Single-dose NEPA found non-inferior to aprepitant/granisetron
MDedge Hematology and Oncology
Developments on the malaria front
MDedge Hematology and Oncology
Kids’ self-reports of symptoms, side effects reliable
MDedge Hematology and Oncology
Tafenoquine reduces relapse risk in patients with P vivax malaria
MDedge Hematology and Oncology
Malaria infection can lead to chronic bone loss
MDedge Hematology and Oncology
Malaria drug could help identify bloodstains
MDedge Hematology and Oncology
Group uses mobile lab to track spread of Zika in Brazil
MDedge Hematology and Oncology
Indian govt. waited months to report Zika cases
MDedge Hematology and Oncology